# Commission Regulation (EC) No 1024/2009 of 29 October 2009 on the authorisation and refusal of authorisation of certain health claims made on food and referring to the reduction of disease risk and to children’s development and health (Text with EEA relevance), Annex II Extent: E+W+S+N.I. REJECTED HEALTH CLAIMS Application — Relevant provisions of Regulation (EC) No 1924/2006 Nutrient, substance, food or food category Claim EFSA opinion reference Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral helps to bring back the normal functioning of the alimentary tract during its microflora disturbances (for example in case of loose stools, after taking antibiotics, in case of intestinal disorders caused by enteric pathogens) EFSA-Q-2008-269 Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral is recommended in order to improve the general immunity by maintaining the microbiological balance EFSA-Q-2008-477 Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral helps to protect the alimentary system against enteric pathogens because of strong antagonistic properties and helps to build the natural intestinal barrier EFSA-Q-2008-478 Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral helps to maintain natural intestinal microflora during travel, changing the climatic zone or a diet, especially in poor hygiene conditions EFSA-Q-2008-479 Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral contains living probiotic bacteria with strong ability to intestinal tract colonisation, isolated from healthy, naturally fed infant EFSA-Q-2008-480 Article 14(1)(b) health claim referring to children’s development and health Mumomega® Mumomega® provides the nourishments that support healthy central nervous system development EFSA-Q-2008-328 Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain coordination EFSA-Q-2008-121 Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain concentration EFSA-Q-2008-317 Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain and support brain development and function EFSA-Q-2008-318 Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain learning ability EFSA-Q-2008-319 Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain and support eye development and function EFSA-Q-2008-320 Article 14(1)(b) health claim referring to children’s development and health Eye q baby® Eye q baby® provides the nourishments that support healthy central nervous system development EFSA-Q-2008-119 Article 14(1)(b) health claim referring to children’s development and health Eye q® Eye q® provides the nourishments that help children to maintain healthy brain functions EFSA-Q-2008-329 Article 14(1)(b) health claim referring to children’s development and health Eye q® Eye q® provides the nourishments that help children to maintain concentration levels EFSA-Q-2008-330 --- Source: https://www.legislation.gov.uk/eur/2009/1024/annex/II (the official version) Page: https://openlegislation.uk/eu-regulation-2009-1024/annex-II Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.